Is Spravato (esketamine) a controlled substance?
Medically reviewed by Drugs.com Last updated on Sep 10, 2019.
Official Answerby Drugs.com
Yes. Spravato (esketamine) is a Schedule III Controlled Substance in the United States.
Spravato is rapid acting nasal spray used conjunction with an oral antidepressant, for use in adults with treatment-resistant depression. It was approved by the FDA in March 2019.
Spravato contains esketamine, which is the s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers (mirror image molecules). The FDA first approved ketamine (Ketalar) in 1970 for use as a rapid-acting general anesthetic, but in more recent times has become known as a drug of abuse (Special K) due to its hallucinogenic properties.
Both esketamine and ketamine are listed under schedule III of the Controlled Substances Act (CSA).
Related Medical Questions
- Klonopin vs Xanax - How are they different?
- Is Trintellix the same as Brintellix?
- Lorazepam vs Xanax: What is the difference?
- How does Abilify MyCite work?
- How is Zulresso administered for the treatment of Postpartum Depression?
- SSRI’s vs SNRI’s - What's the difference between them?
- What is the difference between Prozac and Zoloft?